RYR2 and catecholaminergic polymorphic ventricular tachycardia: For instance suppressing CaMKII activity reduced dispersion of activation in engineered human CPVT heart tissue [40], and inhibiting RyR2 with dantrolene reduced dispersion of repolarization in a guinea pig model of non-ischaemic heart disease [52].